FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953383943> ?p ?o ?g. }

• W2953383943 endingPage "877" @default.
• W2953383943 startingPage "877" @default.
• W2953383943 abstract "Background: The ASPIRE (NCT01080391) phase 3 trial showed the efficacy of carfilzomib, lenalidomide and dexamethasone (KRd) triplet for relapse and refractory multiple myeloma (RRMM). However, little is known about safety and efficacy of KRd outside a clinical trial context. Methods: Herein we report real life results of KRd given to 130 RRMM patients from 12 Sicilian Centers. Results: Median age was 62 years; patients had received a median of two previous lines of treatment (range 1-10) and 52% were refractory to previous treatment. Median number of KRd cycles was 12 (2-29), with a mean duration of treatment of 12 months; 21 patients had received at least 18 cycles. Overall response rate was 61%, including 18% complete response. Median PFS was 22.9 months, median OS was not reached. Creatinine clearance >30 mL/min, quality of the best achieved response and standard Fluorescence In Situ Hybridization (FISH) risk were independent predictors of favorable outcome. Patients who received the full-dosage of carfilzomib in the first two cycles had a better outcome. Conclusions: KRd was effective and well tolerated and in a considerable proportion of patients, therapy continued beyond the 18th cycle. The finding of a better outcome in patients with the higher cumulative dose of carfilzomib in the first two cycle encourages to maintain the maximum tolerated dose." @default.
• W2953383943 created "2019-06-27" @default.
• W2953383943 creator A5000098294 @default.
• W2953383943 creator A5001007530 @default.
• W2953383943 creator A5001923523 @default.
• W2953383943 creator A5003679742 @default.
• W2953383943 creator A5003699463 @default.
• W2953383943 creator A5005395737 @default.
• W2953383943 creator A5012586021 @default.
• W2953383943 creator A5013254549 @default.
• W2953383943 creator A5014280972 @default.
• W2953383943 creator A5014501048 @default.
• W2953383943 creator A5015246061 @default.
• W2953383943 creator A5018769545 @default.
• W2953383943 creator A5019674488 @default.
• W2953383943 creator A5022006811 @default.
• W2953383943 creator A5025699500 @default.
• W2953383943 creator A5025988073 @default.
• W2953383943 creator A5034393745 @default.
• W2953383943 creator A5035572742 @default.
• W2953383943 creator A5035664047 @default.
• W2953383943 creator A5040930723 @default.
• W2953383943 creator A5046522102 @default.
• W2953383943 creator A5049725984 @default.
• W2953383943 creator A5062195312 @default.
• W2953383943 creator A5064125825 @default.
• W2953383943 creator A5072417532 @default.
• W2953383943 creator A5078429053 @default.
• W2953383943 creator A5080194885 @default.
• W2953383943 creator A5090459822 @default.
• W2953383943 date "2019-06-19" @default.
• W2953383943 modified "2023-10-13" @default.
• W2953383943 title "Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network" @default.
• W2953383943 cites W1608379611 @default.
• W2953383943 cites W1985864219 @default.
• W2953383943 cites W2032640560 @default.
• W2953383943 cites W2034889945 @default.
• W2953383943 cites W2037829609 @default.
• W2953383943 cites W2074103505 @default.
• W2953383943 cites W2095255742 @default.
• W2953383943 cites W2096367061 @default.
• W2953383943 cites W2104466948 @default.
• W2953383943 cites W2125721471 @default.
• W2953383943 cites W2140391009 @default.
• W2953383943 cites W2140579395 @default.
• W2953383943 cites W2141105112 @default.
• W2953383943 cites W2169403306 @default.
• W2953383943 cites W2193716145 @default.
• W2953383943 cites W2201190784 @default.
• W2953383943 cites W2343386476 @default.
• W2953383943 cites W2460376887 @default.
• W2953383943 cites W2465965969 @default.
• W2953383943 cites W2486629951 @default.
• W2953383943 cites W2512106959 @default.
• W2953383943 cites W2528329272 @default.
• W2953383943 cites W2588506860 @default.
• W2953383943 cites W2606120108 @default.
• W2953383943 cites W2606454205 @default.
• W2953383943 cites W2737964630 @default.
• W2953383943 cites W2784152305 @default.
• W2953383943 cites W2801224905 @default.
• W2953383943 cites W2805341297 @default.
• W2953383943 cites W2808391935 @default.
• W2953383943 cites W2884976220 @default.
• W2953383943 doi "https://doi.org/10.3390/jcm8060877" @default.
• W2953383943 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6617295" @default.
• W2953383943 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31248142" @default.
• W2953383943 hasPublicationYear "2019" @default.
• W2953383943 type Work @default.
• W2953383943 sameAs 2953383943 @default.
• W2953383943 citedByCount "21" @default.
• W2953383943 countsByYear W29533839432019 @default.
• W2953383943 countsByYear W29533839432020 @default.
• W2953383943 countsByYear W29533839432021 @default.
• W2953383943 countsByYear W29533839432022 @default.
• W2953383943 countsByYear W29533839432023 @default.
• W2953383943 crossrefType "journal-article" @default.
• W2953383943 hasAuthorship W2953383943A5000098294 @default.
• W2953383943 hasAuthorship W2953383943A5001007530 @default.
• W2953383943 hasAuthorship W2953383943A5001923523 @default.
• W2953383943 hasAuthorship W2953383943A5003679742 @default.
• W2953383943 hasAuthorship W2953383943A5003699463 @default.
• W2953383943 hasAuthorship W2953383943A5005395737 @default.
• W2953383943 hasAuthorship W2953383943A5012586021 @default.
• W2953383943 hasAuthorship W2953383943A5013254549 @default.
• W2953383943 hasAuthorship W2953383943A5014280972 @default.
• W2953383943 hasAuthorship W2953383943A5014501048 @default.
• W2953383943 hasAuthorship W2953383943A5015246061 @default.
• W2953383943 hasAuthorship W2953383943A5018769545 @default.
• W2953383943 hasAuthorship W2953383943A5019674488 @default.
• W2953383943 hasAuthorship W2953383943A5022006811 @default.
• W2953383943 hasAuthorship W2953383943A5025699500 @default.
• W2953383943 hasAuthorship W2953383943A5025988073 @default.
• W2953383943 hasAuthorship W2953383943A5034393745 @default.
• W2953383943 hasAuthorship W2953383943A5035572742 @default.
• W2953383943 hasAuthorship W2953383943A5035664047 @default.
• W2953383943 hasAuthorship W2953383943A5040930723 @default.
• W2953383943 hasAuthorship W2953383943A5046522102 @default.

• next